The aging population is rapidly increasing, and it is important to identify dietary factors that can prevent disease and promote health in this group. Legumes, such as peanuts, are a plant-based food high in protein and unsaturated fat making this a healthy choice but are not consumed frequently enough in older adults. Studies have shown that regular nut consumption is associated with lower adiposity and reduced weight gain, and several dietary pattern studies indicate that nuts and legumes are associated with better bone health. In addition, our preliminary translational data indicates that a higher monounsaturated fatty acid (MUFA) intake is associated with improved bone mineral density (BMD) and quality. Given these findings, the proposed study aims to examine the impact of consuming peanut products on bone health, metabolic health (e.g., serum glucose, insulin, lipids and inflammation), markers of brain and sleep health, and physical function in overweight and obese older adults before and after a six-month weight loss intervention using a randomized controlled design. The results of this study have the potential to provide valuable insights into the role of peanuts as a sources of fatty acids in promoting health and preventing disease in at-risk adults.
The aging population is rapidly increasing, and it is important to identify dietary factors that can prevent disease and promote health in this group. Legumes, such as peanuts, are a plant-based food high in protein and unsaturated fat making this a healthy choice but are not consumed frequently enough in older adults. Studies have shown that regular nut consumption is associated with lower adiposity and reduced weight gain, and several dietary pattern studies indicate that nuts and legumes are associated with better bone health. In addition, our preliminary translational data indicates that a higher monounsaturated fatty acid (MUFA) intake is associated with improved bone mineral density (BMD) and quality. Given these findings, the proposed study aims to examine the impact of consuming peanut products on bone health, metabolic health (e.g., serum glucose, insulin, lipids and inflammation), markers of brain and sleep health, and physical function in overweight and obese older adults before and after a six-month weight loss intervention using a randomized controlled design. The results of this study have the potential to provide valuable insights into the role of peanuts as a sources of fatty acids in promoting health and preventing disease in at-risk adults. Specific Aims 1. To determine whether consuming peanuts daily compared to a control group (no nuts) during lifestyle intervention has a differential effect on bone mineral density in older adults who are overweight or obese. 2. To determine the temporal change in bone turnover biomarkers and bone regulating hormones during weight loss in the diet in older adults with overweight or obesity. Exploratory outcomes will examine metabolic biomarkers (serum glucose, insulin, lipid levels), brain (MRI and biomarkers) and sleep health and physical function.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
44
Subjects will receive a daily peanut snack and nutrition education-behavior modification instructions for weight loss
Subjects will receive a daily peanut snack and nutrition education-behavior modification instructions for weight loss
Rutgers University - NJ Inst Food Nutrition & Health
New Brunswick, New Jersey, United States
RECRUITINGBone Mineral Density (BMD - hip)
dual energy x-ray absorptiometry; g/cm2
Time frame: Change from baseline to 24 weeks
Soft tissue (lean and fat mass)
dual energy x-ray absorptiometry (kg)
Time frame: Change from baseline to 24 weeks
Serum bone turnover
Serum levels (ng/mL) of carboxyterminal crosslinking telopeptide of type I collagen (CTX), procollagen type-I aminoterminal propeptide (PINP), and osteocalcin
Time frame: Change from baseline to 24 weeks
Areal BMD
Dual energy x-ray absorptiometry: lumbar spine, femoral neck, radius, total body, g/cm2
Time frame: Change from baseline to 24 weeks
Weight loss
Body weight in kg
Time frame: Change from baseline to 24 weeks
Trabecular BMD
peripheral quantified computed tomography, g/cm3
Time frame: Change from baseline to 24 weeks
Trabecular separation
peripheral quantitative computed tomography, mm
Time frame: Change from baseline to 24 weeks
Trabecular bone volume / tissue volume
peripheral quantitative computed tomography, BV/TV (%)
Time frame: Change from baseline to 24 weeks
Cortical and total (volumetric BMD)
peripheral quantitative computed tomography, g/cm3
Time frame: change from baseline to 24 weeks
Cortical (thickness)
peripheral quantitative computed tomography, mm
Time frame: change from baseline to 24 weeks
Cortical (porosity)
peripheral quantitative computed tomography, %
Time frame: change from baseline to 24 weeks
Inflammatory Markers
Serum levels of high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α)
Time frame: Change from baseline to 24 weeks
Lipid panel
serum LDL, HDL, triglycerides (mg/dL)
Time frame: Change in baseline and 24 weeks
Cognition
Neuropsychological Test Automated Battery (CANTAB)
Time frame: Change from baseline to 24 weeks
Physical and sleep activity level
Time spent in sleep, sedentary activity, and moderate-to-vigorous activity (minutes) using Actigraphy
Time frame: change from baseline to 24 weeks
Sleep architecture (EEG)
Time spent in rapid eye movement (REM) sleep, and non-REM stages 1-3 sleep (minutes) and as a percentage of total sleep time
Time frame: Baseline and 24 weeks
Subjective Sleep
Sleep Diary will be used to assess quality of the previous night's sleep using a Likert scale (higher scores reflect higher quality sleep)
Time frame: Change from baseline to 24 weeks
Body Temperature (CALERA)
(Core, skin, heat flux)
Time frame: Change from baseline to 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.